Not currently recruiting at UCSD

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

a study on Inflammatory Bowel Disease Ulcerative Colitis

Summary

Eligibility
for people ages 18-80 (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
estimated completion
Principal Investigator
by William Sandborn
Headshot of William Sandborn
William Sandborn

Description

Summary

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

Official Title

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

Keywords

Ulcerative Colitis, Inflammatory Bowel Disease, Colitis, Ulcer, Mirikizumab

Eligibility

You can join if…

Open to people ages 18-80

  • Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had at least one study drug administration and have not had early termination of study drug.

  • Female participants must agree to contraception requirements.

    -

You CAN'T join if...

  • Participants must not have developed a new condition, including cancer in the originator study.
  • Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either originator study
  • Participants may not have received surgery for UC in the originator study or are likely to require surgery for treatment of UC during the study.
  • Participants must not have developed adenomatous polyps during the originator study that have not been removed prior to the start of this study.

Locations

  • University of California San Diego not yet accepting patients
    La Jolla California 92093 United States
  • Clinical Applications Laboratories, Inc. completed
    San Diego California 92103 United States

Lead Scientist at UCSD

  • William Sandborn
    Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 911 research publications

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
ID
NCT03519945
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 960 study participants
Last Updated